Abstracts tagged "Myopathies"

Abstract Number: 2674 • ACR Convergence 2025
Pulmonary ultrasound findings and their relationship with clinical characteristics and myopathy antibodies in a cohort of patients with myositis
Ana Mora¹, Carina Soto-Fajardo², Jiram Torres-Ruiz³, Diana Gómez-Martín⁴, Fabian Carranza⁵, Tabata Cano⁶, Elena Cervantes Ramírez⁷, Alejandra Espinosa⁵, Yatzil Reyna Juárez⁸ and Carlos Pineda², ¹National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico, Mexico, ²National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, ³INCMNSZ, Ciudad de México, Mexico, ⁴INCMNSZ, Mexico city, Federal District, Mexico, ⁵National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, ⁶National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Huixquilucan, Mexico, ⁷National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico, ⁸Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by muscular and systemic involvement, with interstitial lung disease (ILD) being a challenging problem.…
Abstract Number: 1889 • ACR Convergence 2025
Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe
Esther Yi¹, Jason Xenakis¹, Chris Blazos², Jade Garratt-Wheeldon², James Piercy², Peter Anderson² and Rohit Aggarwal³, ¹Pfizer Inc., New York, United States of America, New York, ²Adelphi Real World, Bollington, United Kingdom, Bollington, United Kingdom, ³University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of rare autoimmune inflammatory rheumatic diseases, including dermatomyositis (DM).Methods: Data were drawn from the Adelphi Real…
Abstract Number: 0293 • ACR Convergence 2025
Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis
Jackie Weiss¹, Miriam Mende², EunByul Cho³, Guo Shen³, Dmitry Karayev³, Allan L. Metzger³, Robert I. Morris³, Sabine L. Kramp², Cornelia Dähnrich² and Wolfgang Schlumberger², ¹EUROIMMUN US, Mountain Lakes, NJ, ²Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany, ³RDL Reference Laboratory Inc., Los Angeles, CA
Background/Purpose: Sporadic inclusion body myositis (sIBM) is an autoimmune disease manifesting with muscle degeneration, inflammatory infiltrates and inclusion vacuoles. Diagnosis of sIBM is hampered by…
Abstract Number: 2671 • ACR Convergence 2025
Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
Rohit Aggarwal¹, Sebastian Rodriguez-Garcia², Agna Neto³, Despoina Papadopoulou⁴, Ben Van Baelen³, Paul Duncombe³, Leentje De Ceuninck⁵, Bas van der Woning⁶ and Hector Chinoy⁷, ¹University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ²Hospital Universitario de La Princesa, Madrid, Spain, ³argenx, Ghent, Belgium, ⁴argenx, Alimos Attikis, Greece, ⁵argenx, Issy-les-Moulineaux, France, ⁶argenx BV, Boston, MA, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare, systemic, autoimmune, rheumatic disease, with different subtypes, characterized by muscle weakness and extra-muscular involvement. There are no…
Abstract Number: 1772 • ACR Convergence 2025
Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases
Kosaku Murakami¹, Akiko Yoshida², Hitoshi Uga³, Shuji Sumitomo⁴, Koichiro Ohmura⁵, Ryosuke Hiwa⁶, Tomohiro Kozuki⁷, Mao Kuroishi³, Chihiro Suminaka³, Mirei Shirakashi⁶, Hideaki Tsuji⁸, Shuji Akizuki⁶, Ran Nakashima⁶, Hajime Yoshifuji⁶, Akira Onishi⁹, Masao Tanaka⁹, Akio Morinobu¹⁰, Kenji Chamoto⁷ and Tasuku Honjo⁷, ¹Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ²Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Central Research Laboratories, Sysmex corporation, Kobe, Hyogo, Japan, ⁴Kobe City Medical Center General Hospital, Kobe city, Hyogo, Japan, ⁵Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁷Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁰Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Soluble checkpoint molecules (sCM) may be involved in the pathophysiology of autoimmune diseases by inhibiting the suppressive signals of immune cell activation through binding…
Abstract Number: 0292 • ACR Convergence 2025
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
Haley Zimmerman¹, Ethan Ritz², Kristin Wipfler³, Kaleb Michaud⁴ and Didem Saygin¹, ¹Rush University Medical Center, Chicago, IL, ²Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
Abstract Number: 2077 • ACR Convergence 2025
Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Tam Dinh¹, Evelyn Inga¹, Janelle Francisco¹, Yvonne Waters¹, Krystle Tapia², Maheswari Muruganandam³, N. Suzanne Emil¹, Frank O'Sullivan¹ and Wilmer Sibbitt³, ¹University of New Mexico, Albuquerque, ²University of New Mexico Hospital, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is an aggressive subtype of idiopathic inflammatory myopathy (IIM) associated anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies. Recently there have been…
Abstract Number: 1218 • ACR Convergence 2025
Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients
Tsvetelina Velikova¹, Kostadin Kostadinov², Emilia Naseva³, Tamar Rubinstein⁴, Manali Sarkar⁵, Lavanya Mangla⁶, Joanna Makowska⁷, Raphael Micheroli⁸, Leandro ferreryra⁹, Linda Kobert¹⁰, Ioannis Parodis¹¹, Elena Nikiphorou¹², Samuel Shinjo¹³, Carlo Vinicio Caballero Uribe¹⁴, Vincenzo Venerito¹⁵, Vikas Agarwal¹⁶ and Latika Gupta¹⁷, ¹Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ²Department of Social Medicine and Public Health, Faculty of Public Health, Medical University, Plovdiv; Health and Quality of Life in a Green and Sustainable Environment Research Group, Strategic Research and Innovation Program for the Development of MU- Plovdiv, Medical University of Plovdiv, Environmental Health Division, Research Institute at Medical University of Plovdiv, Medical University of Plovdiv,, Plovdiv, Bulgaria, ³Faculty of Public Health, Medical University of Sofia, ¹⁵ Acad. Ivan Evstratiev Geshov, ¹⁶⁰⁶ Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ⁴Albert Einstein College of Medicine, White Plains, NY, ⁵Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁶Maulana Azad Medical College, ²-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, ⁷Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸University Hospital Zurich, Zurich, Switzerland, ⁹HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ¹⁰The Myositis Association, Columbia, MD, ¹¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹²King's College London, London, United Kingdom, ¹³Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹⁴Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ¹⁵Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: The impact of social determinants of health (SDoH)—including socioeconomic status, social support, and geographic context—on disease outcomes in idiopathic inflammatory myopathies (IIM) remains underexplored.…
Abstract Number: 0287 • ACR Convergence 2025
Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
Daniel Alberto Carrillo-Vázquez¹, Beatriz Alcalá-Carmona¹, Jennifer Tiaré Balderas Miranda², Yatzil Reyna Juárez³, María José Ostos Prado¹, Samuel Govea-Peláez¹, Nancy R Mejía Domínguez⁴, Guillermo Juárez Vega⁴, Karina Santana-De Anda¹, Jiram Torres-Ruiz⁵ and Diana Gómez-Martín⁶, ¹Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Ciudad de México, Mexico, ⁶INCMNSZ, Mexico city, Federal District, Mexico
Background/Purpose: Vasculopathic manifestations of idiopathic inflammatory myopathies (IIM) such as interstitial lung disease (ILD), calcinosis, skin ulcers, mechanic’s hands, are characterized by immune-mediated vascular damage.…
Abstract Number: 2073 • ACR Convergence 2025
Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Sabína Oreská¹, Kristina Svobodová¹, Lucia Vernerová¹, Dana Dlouhá², Hana Wunsch¹, Karel Pavelka¹, Jiri Vencovsky³, Ladislav Šenolt⁴, Michal Vrablik⁵, Jaroslav Alois Hubáček² and Michal Tomcik¹, ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵³rd Department of Internal Medicine, General University Hospital and ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammatory muscle injury. Circulating cell-free DNA (cfDNA), including nuclear (cfnDNA) and mitochondrial (cfmtDNA) DNA, has been shown…
Abstract Number: 1210 • ACR Convergence 2025
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Gema María Lledó Ibáñez¹, Jorge Álvarez-Troncoso², Borja del Carmelo Gracia Tello³, Sergio Prieto-Gonzalez⁴, Elena Martínez Robles⁵, Diana Cristina-Varela⁶, Sebastián Molina-Ríos⁷, Luis Sáez Comet⁸, Eiman Soliman⁹, Franklin Uguña¹⁰, Miguel Antonio Mesa¹¹, Miguel Martín Cascón¹², Tânia Santiago¹³, Grace-Jimena Santamaría-Peñaloza¹⁴, Tsvetoslav Georgiev¹⁵, Santiago Bernal-Macias¹⁶, Begoña Marí-Alfonso¹⁷, Jesus Ballano Rodríguez-Solís¹⁸, Sally Patricia Pino Hernández¹⁹, Jacek Olas²⁰, Juan Manuel Mosquera Angarita²¹, Elena García- Guijarro²², Isabel Perales Fraile²³, Mayka Freire Dapena²⁴, Iván Pérez de Pedro²⁵, Luis Adrián Viteri Noël²⁶ and Eduardo Ramos ibáñez²⁷, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Madrid, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Hospital Clinic, Barcelona, Catalonia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, ⁷Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Alexandria Faculty of Medicine, Alexandria, Egypt, ¹⁰Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, ¹¹Universidad Pontificia Bolivariana, Medellin, Colombia, ¹²Hospital General Universitario Morales Meseguer, Murcia, Spain, ¹³ULS de Coimbra, Coimbra, Portugal, ¹⁴Hospital Metropolitano, Quito, Ecuador, ¹⁵Hospital St. Marina, Varna, Varna, Bulgaria, ¹⁶Hospital Universitario San Ignacio, Bogotá, Colombia, ¹⁷Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁸Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, ¹⁹Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, ²⁰MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, ²¹Hospital Sant Joan de Déu, Barcelona, Spain, ²²Hospital Universitario Infanta Cristina, Madrid, Spain, ²³Hospital Universitario Infanta Sofía, Madrid, Spain, ²⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ²⁵Hospital Regional Universitario de Málaga, Málaga, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains…
Abstract Number: 0285 • ACR Convergence 2025
Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
Connor Buechler¹, Nawang Singhe², Lindsey Wanberg², Cody Rasner², Joseph McGrath², Karen Baker-James², Rebecca Freese² and David Pearson³, ¹University of Minnesota, Mendota Heights, MN, ²University of Minnesota, Minneapolis, MN, ³Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Amyopathic dermatomyositis (ADM) is a subset of DM in which cutaneous findings occur without muscle disease for >6 months after diagnosis. However, there is…
Abstract Number: 2072 • ACR Convergence 2025
Results of an Integrated Program for Early Cancer Detection in Idiopathic Inflammatory Myopathies
valeria cantu¹, Rebeca L. Polina-Lugo¹, Emmanuel Dominguez-Chapa², Ana Cecilia Bardan Inchaustegui³, Rosa Arvizu-Rivera⁴, fernanda m. garcia-Carrillo⁵, Ericka S. Reyna-Hernandez⁶, Daniela A. Mejia-Rodriguez⁶, Jesus Alberto Cardenas-de la Garza⁷ and Miguel Villarreal-Alarcón⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, ⁶Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁷Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁸Hospital Universitario UANL, Monterrey, Nuevo León, Mexico
Background/Purpose: Cancer risk is significantly increased in Idiopathic Inflammatory Myopathies (IIM), particularly within the first 3 to 5 years after diagnosis. Given that cancer represents…
Abstract Number: 1211 • ACR Convergence 2025
Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Kristina Svobodová¹, Sabína Oreská¹, Lucia Vernerová², Dana Dlouhá³, Hana Wunsch², Karel Pavelka², Jiri Vencovsky⁴, Ladislav Šenolt⁵, Michal Vrablik⁶, Jaroslav Alois Hubáček³ and Michal Tomcik², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁴Institute of Rheumatology, Praha ⁸, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶³rd Department of Internal Medicine, General University Hospital and ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) involve muscle inflammation. MicroRNAs (miRNAs), such as miR-133a-3p and miR-1-3p, play a key role in gene regulation and muscle repair.…
Abstract Number: 0282 • ACR Convergence 2025
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Shiri Keret¹, Raisa Lomanto Silva², Irada Choudhuri³, Eugenia Gkiaouraki³, Tanya Chandra³, Nantakarn Pongtarakulpanit³, Shreya Sriram³, Niladri Bhowmick³, Vaidehi Kothari³, Kaushik Sreerama Reddy³, Eaman Alhassan⁴, Anushka Aggarwal⁵, Maha Almackenzie⁶, Siamak Moghadam-Kia⁴, Dana Ascherman⁷, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Bnai Zion Medical Center, Atlit, Israel, ²Massachusetts General Hospital, Boston, MA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Indraprastha Apollo Hospital, New Delhi, India, ⁶Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].